ARTICLE | Company News
Ambrilia, Merck infectious news
June 15, 2009 7:00 AM UTC
Merck will return all rights to Ambrilia's protease inhibitor program to treat HIV/AIDS and pay Ambrilia $2 million to settle arbitration pending before the International Chamber of Commerce. Ambrilia...